In another published study, TP53 non-missense mutations reduced responsiveness to first-generation TKIs and worsen the prognosis of EGFR-mutant advanced NSCLC patients (mPFS: 6.3 vs 14 months, P=0.041; HR 2.01, 95% CI: 1.00–4.05, P=0.046; mOS: 21.2 vs 52.5 months, P=0.001; HR 5.53, 95% CI: 1.79–16.95 P=0.001) (34). Here, TP53 is linked to non-small cell lung carcinoma.